London Daily

Focus on the big picture.
Wednesday, Nov 05, 2025

Sunak warns over multibillion cost of booster programme

Sunak warns over multibillion cost of booster programme

Exclusive: Chancellor said to not have opposed jab regime but warned of spending cuts or tax rises to pay for it
Rishi Sunak has issued a stark warning to Department of Health officials over the multibillion-pound cost of regular booster rollouts, the Guardian has learned.

Sources said the chancellor raised the point in several Covid meetings that a mooted three-month booster regime – more frequent than originally anticipated – could begin to impact on future spending.

A Whitehall source from outside the Treasury said Sunak had not opposed the measure but warned prices were likely to rise and that the cost to the exchequer should not be underestimated. They said the additional cost would need to be paid for in either spending cuts or tax rises.

“He made the point, rightly, that people would feel the effects of that spending in NHS and household budgets. These doses do not grow on trees,” the source said.

“Worst case scenario, if a new variant comes along or if Omicron doesn’t burn out, if we have to do this for years to come, that’s billions in costs that has not been foreseen which has to be paid for.”

The increase in national insurance, earmarked for NHS waiting lists but eventually aimed to help tackle the increased costs of social care, is expected to bring in £12bn a year which the Treasury could raid for additional cash for jabs.

This month, the government has signed contracts to buy 114m additional Pfizer/BioNTech and Moderna doses for 2022 and 2023. Those are in addition to the 35m additional doses of Pfizer/BioNTech that were ordered in August for delivery in the second half of next year.

Sunak is said to have raised the point most recently during Wednesday’s meeting about “plan B” measures that more regular booster doses were not built into current spending plans. Additional boosters, should they be required every three to six months, could cost an additional £5bn a year.

The UK does not disclose what it has paid for vaccines, citing commercial confidentiality. Reports have suggested a significant additional cost for the doses, after Pfizer raised prices because of increased demand.

In August, the Financial Times reported Pfizer increased the price of its Covid-19 vaccine by more than a quarter and Moderna by more than a tenth in the latest EU supply contracts.

A Treasury source said: “We are continuing to do whatever it takes to support our fight against Covid, including providing new funding to roll out our booster campaign as quickly as possible to protect people from Omicron. We will also ensure that taxpayers’ money is spent responsibly.”

Sunak is also facing the possibility of having to revive Covid support measures for businesses, which have not been reintroduced under plan B measures because firms are not required to close or enforce social distancing measures that can limit capacity.

Powerful business groups such as the CBI have not made public demands for further support – though footfall numbers have begun to drop and leisure and hospitality are likely to feel the effects of public caution.

The research group Springboard found footfall at UK high streets fell by 2.7% in the week to last Saturday. They had been expecting a Christmas shopping surge on Saturday but that did not materialise, suggesting that concerns over Omicron kept people away.

Demands from business groups, as well as MPs, are likely to increase if Boris Johnson needs to impose further restrictions – even if they do not include business closures.

Lobby groups are likely to argue that stricter social distancing measures or curfews would have a significant financial effect that would need to be compensated.

Sunak’s department was forced to defend itself over the weekend after it emerged that Treasury staff held celebratory drinks after the November budget, in contravention of lockdown rules in England.

A spokesperson said it was a “small number” of staff who celebrated around their desk and Sunak was not aware of the event.
Newsletter

Related Articles

0:00
0:00
Close
Massive Spoilers Emerge from MAFS UK 2025: Couple Swaps, Dating App Leaks and Reunion Bombshells
Kurdish-led Crime Network Operates UK Mini-Marts to Exploit Migrants and Sell Illicit Goods
UK Income Tax Hike Could Trigger £1 Billion Cut to Scotland’s Budget, Warns Finance Secretary
Tommy Robinson Acquitted of Terror-related Charge After Phone PIN Dispute
Boris Johnson Condemns Western Support for Hamas at Jewish Community Conference
HII Welcomes UK’s Westley Group to Strengthen AUKUS Submarine Supply Chain
Tragedy in Serbia: Coach Mladen Žižović Collapses During Match and Dies at 44
Diplo Says He Dated Katy Perry — and Justin Trudeau
Dick Cheney, Former U.S. Vice President, Dies at 84
Trump Calls Title Removal of Andrew ‘Tragic Situation’ Amid Royal Fallout
UK Bonds Rally as Chancellor Reeves Briefs Markets Ahead of November Budget
UK Report Backs Generational Smoking Ban Ahead of Tobacco & Vapes Bill Review
UK’s Domino’s Pizza Group Reports Modest Like-for-Like Sales Growth in Q3
UK Supplies Additional Storm Shadow Missiles to Ukraine as Trump Alleges Russian Underground Nuclear Tests
High-Profile Broodmare Puca Sells for Five Million Dollars at Fasig-Tipton ‘Night of the Stars’
Wilt Chamberlain’s One-of-a-Kind ‘Searcher 1’ Supercar Heads to Auction
Erling Haaland’s Remarkable Run: 13 Premier League Goals in 10 Matches and Eyes on History
UK Labour Peer Warns of Emerging ‘Constituency for Hating Jews’ in Britain
UK Home Secretary Admits Loss of Border Control, Warns Public Trust at Risk
President Trump Expresses Sympathy for UK Royal Family After Title Stripping of Prince Andrew
Former Prince Andrew to Lose His Last Military Title as King Charles Moves to End His Public Role
King Charles Relocates Andrew to Sandringham Estate and Strips Titles Amid Epstein Fallout
Two Arrested After Mass Stabbing on UK Train Leaves Ten Hospitalised
Glamour UK Says ‘Stay Mad Jo x’ After Really Big Rowling Backlash
Former Prince Prince Andrew Faces Possible U.S. Congressional Appearance Over Jeffrey Epstein Inquiry
UK Faces £20 Billion Productivity Shortfall as Brexit’s Impact Deepens
UK Chancellor Rachel Reeves Eyes New Council-Tax Bands for High-Value Homes
UK Braces for Major Storm with Snow, Heavy Rain and Winds as High as 769 Miles Wide
U.S. Secures Key Southeast Asia Agreements to Reshape Rare Earth Supply Chains
US and China Agree One-Year Trade Truce After Trump-Xi Talks
BYD Profit Falls 33 % as Chinese EV Maker Doubles Down on Overseas Markets
US Philanthropists Shift Hundreds of Millions to UK to Evade Regulatory Uncertainty in Trump Era
Israeli Energy Minister Delays $35 Billion Gas Export Agreement with Egypt
King Charles Strips Prince Andrew of Titles and Royal Residence
Trump–Putin Budapest Summit Cancelled After Moscow Memo Raises Conditions for Ukraine Talks
Amazon Shares Soar 11% as Cloud Business Hits Fastest Growth Since 2022
Credit Markets Flooded with More Than $200 Billion of AI-Linked Debt Issuance
U.S. Treasury Secretary Scott Bessent Says China Made 'a Real Mistake' by Threatening Rare-Earth Exports
Report Claims Nearly Two Billion Dollars in Foreign Charity Funds Flowed into U.S. Advocacy Groups
White House Refutes Reports That US Targeting Military Sites in Venezuela
Meta Seeks Dismissal of Strike 3’s $350 Million Copyright Lawsuit
Apple Exceeds Forecasts With $102.5 Billion Q3 Revenue Despite iPhone Miss
Israel's IDF Major General Yifat Tomer-Yerushalmi Admits to Act Amounting to Aiding Hamas During Wartime (Treason)
Shawbrook IPO Marks London’s Biggest UK Listing in Two Years
UK Government Split Over Backing Brazil’s $125 Billion Tropical Forest Fund Ahead of COP30
J.K. Rowling Condemns Glamour UK Feature of Nine Trans Women as 'Men Better at Being Women'
King Charles III Removes Prince Andrew’s Titles and Orders His Departure from Royal Lodge
UK Finance Minister Reeves Releases Email Correspondence to Clarify Rental-Licence Breach
UK and Vietnam Sign Landmark Migration Deal to Fast-Track Returns of Irregular Arrivals
UK Drug-Pricing Overhaul Essential for Life-Sciences Ambition, Says GSK Chief
×